Indaptus Therapeutics
INDP
18 hedge funds and large institutions have $540K invested in Indaptus Therapeutics in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
175% more capital inflows, than outflows
Capital inflows: $56.8K | Capital outflows: $20.6K
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
13% more funds holding
Funds holding: 16 → 18 (+2)
0.62% less ownership
Funds ownership: 5.93% → 5.32% (-0.62%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20.2K |
| 2 |
Two Sigma Securities
New York
|
+$18.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$10.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.26K |
| 5 |
Renaissance Technologies
New York
|
+$667 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$19.1K |
| 2 |
Tower Research Capital (TRC)
New York
|
-$1.49K |
| 3 |
Pine Valley Investments
Marlton,
New Jersey
|
-$64 |
INDP Hedge Fund Activity: Q4 2024 in Review
18 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q4 2024, worth a combined $540K — down 28% from $750K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new INDP positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $20.2K. The largest seller was Citadel Advisors, exiting entirely with an estimated $19.1K sold.
- 18 institutional investors held Indaptus Therapeutics (INDP) as of Q4 2024, up from 16 in Q3 2024.
- Funds reported $540K of Indaptus Therapeutics stock for Q4 2024, down 28% quarter-over-quarter.
- 3 funds opened new Indaptus Therapeutics positions in Q4 2024 and 1 closed out, a net change of +2 holders.
- The largest Indaptus Therapeutics buyer in Q4 2024 was Susquehanna International Group, an estimated $20.2K added.
- The largest Indaptus Therapeutics seller in Q4 2024 was Citadel Advisors, an estimated $19.1K sold.
Based on aggregated 13F filings for Q4 2024.